Pharmaceuticals News and Research

RSS

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2010.

21 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

Venn Life Sciences acquires French CRO

Venn Life Sciences a multinational Clinical Research Organisation (CRO) announced today that it has acquired French CRO, DCI.

21 Oct 2010

ISCTM to develop solutions for CNS clinical trial methodology

The International Society for CNS Clinical Trials and Methodology (ISCTM) met recently to develop solutions to challenges facing CNS clinical trial methodology.

21 Oct 2010

New PharmaDeals v4 online resource to support pharmaceutical industry

In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.

21 Oct 2010

Nonprescription drug manufacturing and marketing costs increase: Kline

A number of costs associated with nonprescription drug manufacturing and marketing have increased over the past two and a half years. Certain material costs for plastic bottles and blister packs have risen by double digits during this time, increasing packaging expenses.

21 Oct 2010

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

MAP Pharmaceuticals, Inc. today announced that the Company will present nine analyses relating to its LEVADEX™ orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

21 Oct 2010

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

Marc K. Hellerstein, M.D., Ph.D. Co-Founder and Chief of SAB, Kinemed, Inc. presented an "Updated Strategy for Using Disease Predictive Translational Biomarkers in the Rapidly Advancing Field of Causal Pathway Measurements" at the 2010 Personalized and Translational Medicine Conference. In Boston, on September 20-21, 2010.

21 Oct 2010

Link between low testosterone and heart disease deaths: Study

In a new study it was seen that men diagnosed with coronary heart disease with low testosterone were almost twice as likely to die over a seven year period. The team led by Prof Kevin Channer a cardiologist of the Royal Hallamshire Hospital in Sheffield looked at 930 men for the study. This study is in contrast to the popular belief that testosterone increases heart disease risk. The study was published in the journal Online First Heart.

21 Oct 2010

Victorian Government grants assist companies build global markets

The Brumby Labor Government is providing $410,000 in grants to help three Melbourne companies improve their global competitiveness, save money on production costs and create local jobs.

21 Oct 2010

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion Pharmaceuticals, Inc. today announced that its two open-label Phase 2 studies investigating eculizumab (Soliris) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) have met the primary and key secondary endpoints with high clinical and statistical significance, in interim analyses.

21 Oct 2010

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

20 Oct 2010

Cipla launches generic Pirfenidone for IPF

Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF.

20 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

20 Oct 2010

Pharmaceuticals News and Research

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

Venn Life Sciences acquires French CRO

ISCTM to develop solutions for CNS clinical trial methodology

New PharmaDeals v4 online resource to support pharmaceutical industry

Nonprescription drug manufacturing and marketing costs increase: Kline

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

Link between low testosterone and heart disease deaths: Study

Victorian Government grants assist companies build global markets

FDA issues complete response letter for BYDUREON NDA

Genzyme third quarter revenue increases to $1.0 billion

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Cipla launches generic Pirfenidone for IPF

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence